This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Immuneering develops oncology therapeutics targeting the RAS/MAPK signaling pathway. Its lead candidate IMM-1-104 is an oral, once-daily dual-MEK inhibitor that also disrupts KSR1/2 scaffolding proteins, currently in a Phase 1/2a study across multiple solid tumor types including pancreatic cancer, melanoma, and NSCLC. Initial Phase 2a data showed complete and partial responses in first-line pancreatic cancer patients treated with IMM-1-104 plus chemotherapy, and 64% overall survival at 12 months. The company also advances IMM-6-415 for additional oncology indications. Preclinical animal testing was central to IMM-1-104's development: the compound demonstrated broad activity in animal models bearing tumors with diverse RAS and RAF mutations including KRAS-G12C, KRAS-G12D, and BRAF-V600E, and showed superior activity and tolerability versus FDA-registered MEK inhibitors in head-to-head animal studies.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.